Abstract:The disease coronavirus disease 2019 (COVID-19) is a severe respiratory illness that has emerged as a devastating health problem worldwide. The disease outcome is heterogeneous, and severity is likely dependent on the immunity of infected individuals and comorbidities. Although symptoms of the disease are primarily associated with respiratory problems, additional infection or failure of other vital organs are being reported. Emerging reports suggest a quite common co-existence of gastrointestinal (GI) tract symptoms in addition to respiratory symptoms in many COVID-19 patients, and some patients show just the GI symptoms. The possible cause of the GI symptoms could be due to direct infection of the epithelial cells of the gut, which is supported by the fact that (1) The intestinal epithelium expresses a high level of angiotensin-converting enzyme-2 and transmembrane protease serine 2 protein that are required for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into the cells; (2) About half of the severe COVID-19 patients show viral RNA in their feces and various parts of the GI tract; and (3) SARS-CoV-2 can directly infect gut epithelial cells in vitro (gut epithelial cells and organoids) and in vivo (rhesus monkey). The GI tract seems to be a site of active innate and adaptive immune responses to SARS-CoV-2 as clinically, stool samples of COVID-19 patients possess proinflammatory cytokines (interleukin 8), calprotectin (neutrophils activity), and immunoglobulin A antibodies. In addition to direct immune activation by the virus, impairment of GI epithelium integrity can evoke immune response under the influence of systemic cytokines, hypoxia, and changes in gut microbiota (dysbiosis) due to infection of the respiratory system, which is confirmed by the observation that not all of the GI symptomatic patients are viral RNA positive. This review comprehensively summarizes the possible GI immunomodulation by SARS-CoV-2 that could lead to GI symptoms, their association with disease severity, and potential therapeutic interventions.

Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19

Gut Microbiome and COVID 19 Role of Probiotics on Gut Lung Axis

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Microbiota Modulation of the Gut-Lung Axis in COVID-19

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential

Potential Associations Between Microbiome and COVID-19

Roles of the gut microbiota in severe SARS-CoV-2 infection

Effective Regulation of Gut Microbiota With Probiotics and Prebiotics May Prevent or Alleviate COVID-19 Through the Gut-Lung Axis

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Integrated Analysis of Gut Microbiome and Host Immune Responses in COVID-19

Gut microbiota composition is associated with disease severity and host immune responses in COVID-19

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

COVID-19: gastrointestinal symptoms from the view of gut-lung axis

The lung-gut axis and COVID-19

Traditional Chinese medicine against COVID-19: Role of the gut microbiota

COVID-19 and gut immunomodulation

Intestinal Flora As a Potential Strategy to Fight SARS-CoV-2 Infection

Gut-lung axis and dysbiosis in COVID-19

Review Article: Probiotics, Prebiotics and Dietary Approaches During COVID-19 Pandemic

Intermodulation of gut-lung axis microbiome and the implications of biotics to combat COVID-19